Company: CERO
Filing Date: 2025-04-28
Form Type: 10-K/A
Source: 0001213900-25-036075
Chunk: 18

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-28
Form: 10-K/A
Chunk 18
---
 submit concerns anonymously about questionable accounting or audit 
 matters;                                                                                                  |

| ● | reviewing and discussing policies on risk assessment and risk management; |

| ● | reviewing related party transactions; |

| ● | obtaining and reviewing a report by the independent registered public accounting firm at least annually                                 
 that describes the internal quality-control procedures, any material issues with such procedures, and any steps taken to deal with such 
 issues when required by applicable law; and                                                                                             |

| ● | approving (or, as permitted, pre-approving) all audit and all permissible non-audit service to be performed 
 by the independent registered public accounting firm.                                                       |

Compensation Committee The members of our Compensation Committee are Ms. LaPorte, Dr. Rolfe and Mr. Patel. Ms. LaPorte serves as the chairperson of the Compensation Committee. Our board of directors has determined that each of Ms. LaPorte, Dr. Rolfe and Mr. Patel is independent under the applicable Nasdaq listing standards and is a “non-employee director” as defined in Rule 16b-3 promulgated under the Exchange Act. Our Compensation Committee’s main function is to oversee our compensation structure, policies and programs and to review the processes and procedures for the consideration and determination of director and executive compensation. The Compensation Committee’s responsibilities include, among other things:

| ● | recommending to the board of directors goals and objectives, non-equity compensation, and equity grants 
 of all senior officers;                                                                                 |

| ● | recommending to the board of directors goals and objectives, non-equity compensation, and equity grants 
 for the Chief Executive Officer;                                                                        |

| ● | recommending to the board of directors non-equity compensation and equity grants for the directors; |

| ● | reviewing and discussing with the board of directors corporate succession plans for the Chief Executive 
 Officer and key officers;                                                                               |

| ● | reviewing and discussing with management its talent development and related initiatives; |

| ● | assisting the board of directors with its oversight of our strategies, programs, and initiatives related 
 to employee health, safety, and well-being, engagement, pay equity, and diversity and inclusion;         |

| ● | selecting independent compensation consultants and assessing whether there are any conflicts of interest 
 with any of the Compensation Committee’s compensation advisors;                                          |

| ● | reviewing and recommending to the board of directors employment agreements, severance arrangements and             
 change-of-control agreements or provisions for executive officers and other senior management, as appropriate; and |

| ● | reviewing the policies